Deregulated systemic IL-10/IL-12 balance in advanced and poor prognosis paediatric soft tissue sarcomas

References

• Asadullah K, Sterry W, Volk HD. (2003). Interleukin-10 therapy – review of a new approach. Pharmacol Rev 55:241–69
   PubMed Web of Science ®Google Scholar
• Becker Y. (2006). Molecular immunological approaches to biotherapy of human cancers – a review, hypothesis and implications. Anticancer Res 26:1113–34
   PubMed Web of Science ®Google Scholar
• Bermudes-Morales VH, Peralta-Zaragoza O, Alcocer-Gonzalez JM, et al. (2011). IL-10 expression is regulated by HPV E2 protein in cervical cancer cells. Mol Med Report 4:369–75
   Google Scholar
• Bien E, Balcerska A, Adamkiewicz-Drozynska E, et al. (2009). Pre-treatment levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias. Clin Biochem 42:1144–57
   PubMed Web of Science ®Google Scholar
• Bien E, Rapala M, Krawczyk M, Balcerska A. (2010). The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas. J Cancer Res Clin Oncol 136:293–305. Erratum in: J Cancer Res Clin Oncol 2010;136:307
   Google Scholar
• Boonstra A, Rajsbaum R, Holman M, et al. (2006). Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol 177:7551–8
   PubMed Web of Science ®Google Scholar
• Bozkurt N, Yuce K, Basaran M, et al. (2006). Correlation of serum and ascitic IL-12 levels with second-look laparotomy results and disease progression in advanced epithelial ovarian cancer patients. Int J Gynecol Cancer 16:83–6
   PubMed Web of Science ®Google Scholar
• Cervenak L, Morbidelli L, Donati D, et al. (2000). Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood 96:2568–73
   PubMed Web of Science ®Google Scholar
• Chamoto K, Tsuji T, Funamoto H, et al. (2004). Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 64:386–90
   PubMed Web of Science ®Google Scholar
• Cocco C, Pistoia V, Airoldi I. (2009). New perspectives for melanoma immunotherapy: role of IL-12. Curr Mol Med 9:459–69
   PubMed Web of Science ®Google Scholar
• Colombo MP, Trinchieri G. (2002). Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:155–68
   PubMed Web of Science ®Google Scholar
• Del Prete G, De Carli M, Almerigogna F, et al. (1993). Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150:353–60
   PubMed Web of Science ®Google Scholar
• Del Vecchio M, Bajetta E, Canova S, et al. (2007). Interleukin-12: biological properties and clinical application. Clin Cancer Res 13:4677–85
   PubMed Web of Science ®Google Scholar
• Dent LA. (2002). For better or worse: common determinants influencing health and disease in parasitic infections, asthma and reproductive biology. J Reprod Immunol 57:255–72
   PubMedGoogle Scholar
• Ding L, Linsley PS, Huang LY, et al. (1993). IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 151:1224–34
   PubMed Web of Science ®Google Scholar
• Ebert EC. (2000). IL-10 enhances IL-2-induced proliferation and cytotoxicity by human intestinal lymphocytes. Clin Exp Immunol 119:426–32
   PubMed Web of Science ®Google Scholar
• Ebrahimi B, Tucker SL, Li D, et al. (2004). Cytokines in pancreatic carcinoma correlation with phenotypic characteristics and prognosis. Cancer 101:2727–36
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Zlotnik A, Mosmann TR, et al. (1991). IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815–22
   PubMed Web of Science ®Google Scholar
• Garcia-Hernandez ML, Hemandez-Pando R, Gariglio P, Berumen J. (2002). Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumor and vascular cell proliferation. Immunology 105:231–43
   PubMedGoogle Scholar
• Gerlini G, Tun-kyi A, Dudli C, et al. (2004). Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 165:1853–63
   PubMed Web of Science ®Google Scholar
• Gianotti L, Fortis C, Braga M, et al. (1997). Radical oncologic surgery affects the circulatory levels of interleukin 10. J Surg Oncol 66:244–7
   PubMed Web of Science ®Google Scholar
• Gollob JA, Veenstra KG, Parker RA, et al. (2003). Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 21:2564–73
   PubMed Web of Science ®Google Scholar
• Guida M, Casamassima A, Monticelli G, et al. (2007). Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med 5:51 . DOI: 10.1186/1479-5876-5-51
   PubMed Web of Science ®Google Scholar
• Guney N, Soydinc HO, Basaran M, et al. (2009). Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin’s lymphoma. Asian Pac J Cancer Prev 10:669–74
   Google Scholar
• Guo QY, Yuan M, Peng J, et al. (2011). Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma. J Exp Clin Cancer Res 30:24 . DOI: 10.1186/1756-9966-30-24
   PubMed Web of Science ®Google Scholar
• Harmer MH. (1982). TNM classification of pediatric tumors. Geneva, Switzerland: UICC International Union Against Cancer
   Google Scholar
• Hatanaka H, Abe Y, Kamiya T, et al. (2000). Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11:815–19
   PubMed Web of Science ®Google Scholar
• He Y, Hu CH. (2001). Level change of IL-10, IL-12 and TNF alpha in the serum of patients with hepatocellular carcinoma. Hunan Yi Ke Da Xue Xue Bao 26:57–8
   Google Scholar
• Hsia CY, Huo TI, Chiang SY, et al. (2007). Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 33:208–12
   PubMed Web of Science ®Google Scholar
• Hu M, Polyak K. (2008). Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18:27–34
   Google Scholar
• Huang C, Ramakrishnan R, Trkulja M, et al. (2012). Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. Cancer Immunol Immunother 61:573–9
   Google Scholar
• Ikeguchi M, Hatada T, Yamamoto M, et al. (2009). Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 12:95–100
   PubMed Web of Science ®Google Scholar
• Itakura E, Huang RR, Wen DR, et al. (2011). IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol 24:801–9
   PubMed Web of Science ®Google Scholar
• Jebreel A, Mistry D, Loke D, et al. (2007). Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol 121:246–52
   PubMed Web of Science ®Google Scholar
• Kallio JP, Tammela TL, Marttinen AT, Kellokumpu-Lehtinen PL. (2001). Soluble immunological parameters and early prognosis of renal cell cancer patients. J Exp Clin Cancer Res 20:523–8
   PubMedGoogle Scholar
• Kim Y, Stolarska MA, Othmer HG. (2011). The role of the microenvironment in tumor growth and invasion. Prog Biophys Mol Biol 106:353–79
   Google Scholar
• Komp DM, Shapiro E, McNamara J. (1988). Soluble interleukin-2 receptor in childhood non-Hodgkin’s lymphoma. Blood 71:1172–4
   PubMedGoogle Scholar
• Koscielniak E, Morgan M, Treuner J. (2002). Soft tissue sarcoma in children: prognosis and management. Paediatr Drugs 4:21–8
   PubMedGoogle Scholar
• Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. (2003). Concentration of interleukin-6 (IL 6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 48:82–4
   PubMedGoogle Scholar
• Kumar R, Kamdard D, Madden L, et al. (2006). Th1/Th2 cytokine imbalance in melingioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep 15:1513–16
   PubMed Web of Science ®Google Scholar
• Lathers DM, Achille NJ, Young MR. (2003). Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 64:1160–6
   PubMed Web of Science ®Google Scholar
• Lauerova L, Dusek L, Simickova M, et al. (2002). Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 49:159–66
   PubMed Web of Science ®Google Scholar
• Lech-Maranda E, Bienvenu J, Michallet AS, et al. (2006). Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw 17:60–6
   PubMed Web of Science ®Google Scholar
• Li J, Thompson TD, Miller JW, et al. (2008). Cancer incidence among children and adolescents in the United States, 2001–2003. Pediatrics 121:1470–7
   PubMed Web of Science ®Google Scholar
• Mahipal A, Terai M, Berd D, et al. (2011). Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother 60:1039–45
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, et al. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549–55
   PubMed Web of Science ®Google Scholar
• Mapara MY, Sykes M. (2004). Tolerance and cancer: mechanism of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22:1136–51
   PubMed Web of Science ®Google Scholar
• Marchi LH, Paschoalin T, Travessos LR, Rodrigues EG. (2011). Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma. Cancer Gene Ther 18:110–22
   Google Scholar
• Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. (2000). Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273
   PubMedGoogle Scholar
• Masood R, Zhang Y, Bond MW, et al. (1995). Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 85:3423–30
   PubMed Web of Science ®Google Scholar
• Maurer HM, Crist W, Lawrence W, et al. (1988). The Intergroup Rhabdomyosarcoma Study I: a final report. Cancer 61:209–20
   PubMed Web of Science ®Google Scholar
• Mbeunkui F, Johann Jr DJ. (2009). Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63:571–82
   PubMed Web of Science ®Google Scholar
• Mocellin S, Marincola FM, Young HA. (2005). Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78:1043–51
   PubMed Web of Science ®Google Scholar
• Mocellin S, Panelli MC, Wang E, et al. (2003). The dual role of IL-10. Trends Immunol 24:36–43
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765
   PubMed Web of Science ®Google Scholar
• Mortarini R, Borri A, Tragni G, et al. (2000). Peripheral burst of tumor specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8 + T cells in melanoma patients receiving interleukin 12. Cancer Res 60:3559–68
   PubMed Web of Science ®Google Scholar
• Moser M, Murphy KM. (2000). Dendritic cell regulation of TH1-TH2 development. Nat Immunol 1:199–205
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Coffman RL. (1989). TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145–73
   PubMed Web of Science ®Google Scholar
• Muranski P, Restifo NP. (2009). Adoptive immunotherapy of cancer using CD4 + T cells. Curr Opin Immunol 21:200–8
   PubMed Web of Science ®Google Scholar
• Mustea A, Könsgen D, Braicu EI, et al. (2006). Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 26:1715–18
   PubMed Web of Science ®Google Scholar
• Nacinovic-Duletic A, Stifter S, Dvornik S, et al. (2008). Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B cell lymphoma. Int J Lab Hematol 30:230–9
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Inoue Y, Nagashima N, et al. (2004). Relationship between local and systemic expression of interleukin-12 and plasma levels of vascular endothelial growth factor in patients with gastric cancer. Anticancer Res 24:3289–94
   Google Scholar
• Nemunaitis J, Fong T, Shabe P, et al. (2001). Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 19:239–47
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Hirao M, Robbins PD, et al. (1999). Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 59:4035–41
   PubMed Web of Science ®Google Scholar
• O’Garra A, Stapleton G, Dhar V, et al. (1990). Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol 2:821–32
   PubMed Web of Science ®Google Scholar
• O’Hara RJ, Greenman J, MacDonald AW, et al. (1998). Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 4:1943–8
   PubMed Web of Science ®Google Scholar
• Poch B, Lotspeich E, Ramadani M, et al. (2007). Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch Surg 392:353–8
   PubMed Web of Science ®Google Scholar
• Protti MP, De Monte L. (2012). Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer. Oncoimmunology 1:89–91
   PubMed Web of Science ®Google Scholar
• Rabinovich A, Medina L, Piura B. Huleihel M. (2010). Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 21:122–8
   PubMed Web of Science ®Google Scholar
• Romagnani S. (2000). T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 85:9–18
   PubMed Web of Science ®Google Scholar
• Ruka W, Rutkowski P, Kaminska J, et al. (2001). Alterations of routine blond tests in adult patients with soft tissue sarcomas: relationships to cytokine serum levels and prognostic significance. Ann Oncol 12:1423–32
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Kaminska J, Kowalska M, et al. (2002). Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer 100:463–71
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Kaminska J, Kowalska M, et al. (2003). Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol 84:151–9
   PubMed Web of Science ®Google Scholar
• Sakamoto T, Saito H, Tatebe S, et al. (2006). Interleukin-10 expression significantly correlates with minor CD8 + T-cell infiltration and high microvessel density in patients with gastric cancer. Int J Cancer 118:1909–14
   Google Scholar
• Santin AD, Hermonat PL, Ravaggi A, et al. (2000). Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 74:4729–37
   PubMed Web of Science ®Google Scholar
• Saraiva M, Christensen JR, Veldhoen M, et al. (2009). Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31:209–19
   PubMedGoogle Scholar
• Sato T, Terai M, Tamura Y, et al. (2011). Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 51:170–82
   PubMed Web of Science ®Google Scholar
• Sharma A, Khan R, Joshi S, et al. (2010). Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk Lymphoma 51:920–7
   PubMed Web of Science ®Google Scholar
• Shibata M, Nezu T, Kanou H, et al. (2002). Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. Clin Gastroenterol 34:416–20
   Google Scholar
• Smith MA, Seibel NL, Altekruse SF, et al. (2010). Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28:2625–34
   PubMed Web of Science ®Google Scholar
• Sparano A, Lathers DM, Achille N, et al. (2004). Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolayngol Head Neck Surg 131:573–6
   PubMed Web of Science ®Google Scholar
• Spellman JE, Gollnick SO, Zhang PJ, Tomasi TB. (1996). Cytokine production by human soft tissue sarcomas: implications for immunosuppression within the tumour bed. Surg Oncol 5:237–44
   PubMed Web of Science ®Google Scholar
• Stanilov N, Miteva L, Deliysky T, et al. (2010). Advanced colorectal cancer is associated with enhanced IL-23 and IL-10 serum levels. Lab Med 41:159–63
   Web of Science ®Google Scholar
• Steding CE, Wu ST, Zhang Y, et al. (2011). The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 133:221–38
   PubMed Web of Science ®Google Scholar
• Svobodova S, Topolcan O, Holubec Jr L, et al. (2011). Parameters of biological activity in colorectal cancer. Anticancer Res 31:373–8
   Google Scholar
• Szaflarska A, Szczepanik A, Siedlar M, et al. (2009). Preoperative plasma level of IL-10 but not of proinflammatory cytokines is an independent prognostic factor in patients with gastric cancer. Anticancer Res 29:5005–12
   Google Scholar
• Tsuboi K, Miyazaki T, Nakajima M, et al. (2004). Serum interleukin-12 and interleukin-18 levels as a tumour marker in patients with esophageal carcinoma. Cancer Lett 205:207–14
   PubMedGoogle Scholar
• Waldmann TA. (2007). Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immuno 27:1–18
   PubMed Web of Science ®Google Scholar
• Wang R, Lu M, Zhang J, et al. (2011). Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res 30:62 . DOI: 10.1186/1756-9966-30-62
   PubMed Web of Science ®Google Scholar
• Whiteside TL. (2006). Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3–15
   PubMed Web of Science ®Google Scholar
• Witz IP. (2009). The tumor microenvironment: the making of a paradigm. Cancer Microenviron 2:9–17
   Google Scholar
• Yang L, Carbone DP. (2004). Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13–27
   PubMed Web of Science ®Google Scholar
• Zakrzewska I, Poznański J. (2003). Serum levels of interleukin-10 in patients with ovarian carcinoma in response to chemotherapy. Przegl Lek 60:18–20
   Google Scholar
• Zitvogel L, Tahara H, Robbins PD, et al. (1995). Cancer immunotherapy of established tumors with IL 12. Effective delivery by genetically engineered fibroblasts. J Immunol 155:1393–403
   PubMed Web of Science ®Google Scholar